Clinical stage biopharmaceutical company Paradigm Biopharmaceuticals (ASX: PAR) has been given the green light to go ahead with a Phase…
Clinical data trials being conducted by Paradigm Biopharmaceuticals (ASX: PAR) continue to deliver impressive patient outcomes for sufferers of chronic…
Professional athletes may soon have a new treatment for knee osteoarthritis after Paradigm Biopharmaceuticals (ASX: PAR) received glowing endorsements from…